Lisata Therapeutics, based in Basking Ridge, New Jersey, focuses on developing therapies for advanced solid tumors, with its lead candidate LSTA1 enhancing anti-cancer drug penetration in tumors. The company also explores CD34+ cell therapy for various diseases, including critical limb ischemia and diabetic kidney disease.
LSTA has been in the news recently: Lisata Therapeutics, Inc. will present its innovative therapies for advanced solid tumors at two events in September 2024. Meanwhile, ZTI Biosciences has partnered with EF Hutton for strategic and financial advisory services to support its cancer therapy pipeline as it enters clinical trials in the U.S.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
